BioXcel Therapeutics (BTAI) Other Working Capital Changes (2021 - 2026)
BioXcel Therapeutics' (BTAI) quarterly Other Working Capital Changes came in at -$65000.0 in Q1 2026, up 27.78% year-on-year from -$50869.6 in Q1 2025, and up 31.58% quarter-over-quarter from -$95000.0 in Q4 2025.
BioXcel Therapeutics (BTAI) Other Working Capital Changes (2021 - 2026) Analysis & Trends
BioXcel Therapeutics' Other Working Capital Changes history runs 6 years deep, the most recent figure standing at -$65000.0 for Q1 2026.
- On a quarterly basis, Other Working Capital Changes rose 27.78% year-over-year to -$65000.0 in Q1 2026; TTM through Mar 2026 was -$349000.0, a 1.13% increase from a year earlier, with the FY2025 full-year figure at -$374000.0, down 8.09% from the prior year.
- Other Working Capital Changes grew to -$65000.0 in Q1 2026 per BTAI's latest filing, from -$95000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $8.3 million in Q4 2025 and bottomed at -$2.3 million in Q3 2023.
- The 5-year median for Other Working Capital Changes is $459000.0 (2024), against an average of $710823.5.
- Across the five-year window, Other Working Capital Changes fell 10.13% in 2024 and grew 27.78% in 2026, its largest moves.
- Year by year, Other Working Capital Changes stood at -$75000.0 in 2022, then slipped by 9.33% to -$82000.0 in 2023, then slipped by 7.32% to -$88000.0 in 2024, then retreated by 7.95% to -$95000.0 in 2025, then jumped by 31.58% to -$65000.0 in 2026.
- Per Business Quant, the three latest BTAI Other Working Capital Changes figures stand at -$65000.0 (Q1 2026), -$95000.0 (Q4 2025), and -$96000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | BioXcel Therapeutics | 10.62 Mn | 10.62 Mn | -77,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65,000.00 |
| Mar 31, 2026 | -65,000.00 |
| Mar 31, 2026 | -65,000.00 |
| Dec 31, 2025 | -95,000.00 |
| Dec 31, 2025 | -95,000.00 |
| Dec 31, 2025 | -95,000.00 |
| Sep 30, 2025 | -96,000.00 |
| Sep 30, 2025 | -96,000.00 |
| Sep 30, 2025 | -96,000.00 |
| Jun 30, 2025 | -93,000.00 |
| Jun 30, 2025 | -93,000.00 |
| Jun 30, 2025 | -93,000.00 |
| Mar 31, 2025 | -90,000.00 |
| Mar 31, 2025 | -90,000.00 |
| Mar 31, 2025 | -90,000.00 |
| Dec 31, 2024 | -88,000.00 |
| Dec 31, 2024 | -88,000.00 |
| Dec 31, 2024 | -88,000.00 |
| Sep 30, 2024 | -88,000.00 |
| Sep 30, 2024 | -88,000.00 |